Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30, 2026

About this update from Median Technologies

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. SOPHIA ANTIPOLIS, France, July 06, 2026--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): (*) Class E preference shares are non-voting(**) pursuant to article 223-11 of the AMF's General Regulations Furthermore, as of June 30, 2026, out of the 14,424,541 warrants (BSA) issued in connection with the 2025 capital increase, 12,261,125 remained outstanding and exercisable. About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260706559597/en/ Contacts Median Technologies Emmanuelle LeyguesVP, Corporate Marketing & Financial Communications+33 6 10 93 58 [email protected] Investors – SEITOSEI ACTIFIN Ghislaine Gasparetto+33 6 85 36 76 [email protected] Press – MAARC Bruno Arabian+33 6 87 88 47 [email protected]

View stock analysis, news, and events for Median Technologies